RxTran White Paper Highlights Pharmacy Language Access as Patient Safety Risk
A new white paper from RxTran, a division of Language Scientific, warns that unverified prescription translations pose a significant patient safety risk, urging industry and legislative action.
RxTran, a division of Language Scientific, has released a white paper identifying unverified prescription language access as a critical patient safety issue. The report, titled "Pharmacy Language Access Is a Code-Red Patient Safety Problem," argues that current practices in translating prescription information fall short of ensuring patient safety, especially as more states enact laws requiring translated prescription labels.
The paper highlights the potential for severe medical errors and adverse events when patients cannot fully understand their medication instructions due to inaccurate or incomplete translations. It calls on pharmacists, healthcare providers, and legislators to recognize this as a clinical risk equivalent to other major safety concerns in healthcare.
RxTran's findings suggest that the increasing regulatory focus on translated labels needs to be matched by a deeper understanding of the complexities involved in accurate pharmaceutical communication. The company advocates for standardized, verified translation processes to mitigate the risks associated with language barriers in medication management.
The white paper's release comes at a time when healthcare systems are grappling with how to best serve diverse patient populations. RxTran, through its division, aims to provide solutions and raise awareness about the urgent need for reliable language services in pharmacies nationwide.